ASH 2021 | Overcoming T-cell exhaustion with iPSC technology in the treatment of myeloma
Jooeun Bae
• 29 Nov 2021
In this video, Jooeun Bae, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly highlights the challenges associated with CAR-T therapy, drawing focus on T-cell exhaustion and the limitations this puts on CAR-T. Dr Bae then explains how the use of induced pluripotent stem cell (iPSC) technology allows for T-cells to be rejuvenated while overcoming the challenge of T-cell exhaustion, and the benefits that this technology can bring to the treatment of patients with myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
